9 2004 PTO/SB/21 (02-04)
Approved for use through 07/31/2006 OMR 0651-0031

Under the Paperwork Schooling Activities Activities	no nersons are re	U.S. Paten equired to respond to a collection	t and Tra	demark	Office; U.S. D	EPARTMENT	OF COMMERCE		
Under the I stockwork who was a stock with the stoc		Application Number		10/712,494					
TRANSMITTAL	Filin	ng Date	November 13, 2003						
FORM		t Named Inventor	Doris Brugger						
(to be used for all correspondence after initial filing)		Unit		764					
	Exa	miner Name							
Total Number of Pages in This Submission	Atto	rney Docket Number	21	1487	US				
	ENCLOSI	URES (Check all that	apply)						
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawir Licens Petitio Petitio Provis Chang Termir Reque	ng(s) sing-related Papers	ess		to Group Appeal Cor of Appeals Appeal Cor (Appeal Not Proprietary Status Letter	osure(s) (ple	n to Board ences n to Group ply Brief)		
	TURE OF A	PPLICANT, ATTORNI	EY, OF	R AGE	NT				
or Individual name Dennis P. Tran	naloni								
Signature	Tow								
Date 7/27/84							•		
C	ERTIFICATE	OF TRANSMISSION	/MAIL	ING		-			
I hereby certify that this correspondence is I sufficient postage as first class mail in an er the date shown below.	eing facsimile tr	ansmitted to the USPTO or	deposit	ed with					
Typed or printed name Dennis P	Tramalon	i _							
Signature	0-1				Date	7/27	7/04		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT APPLICATION

Examiner:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s): Doris Brugger et al Group:1764

Serial No. 10/712,494, filed November 13, 2003

(Reference No. 21487 US)

For: POSITIONAL ISOMERS OF PEGYLATED ALPHA INTERFERON

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 Date 7/27/04

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the document listed on enclosed Form PTO-1449.

Document C7 listed on Form PTO-1449 is enclosed.

Enclosed is a PCT Written Opinion, dated June 28, 2004, which was issued by the European Patent Office in PCT/EP 03/12498 application corresponding to the captioned application. The PCT Written Opinion lists Documents C3, C5-C7. Document C3 is not being submitted because it has been made of record in an Information Disclosure statement sent to the USPTO on February 10, 2004. Documents C5 and C6 also are not being submitted because they have been made of record in a Supplemental Disclosure Statement sent to the USPTO on May 19, 2004.

Serial No. 10/712,494

Filed: November 13, 2003

Consideration of the document cited on Form PTO-1449 is requested.

Since the Supplemental Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application and/or because each item of information contained in the Supplemental Information Disclosure Statement was cited in a communication for the first time from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement, no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Dennis P. Tramaloni

(Reg. No. 28,542) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-4475

Telefax: (973) 235-2363

144464

JUL 2 9 2004 Substitute for form 1449A/PTO
INFORMATION DISCLOSURE TRADE Complete if Known pplication Number 10/712,494 STATEMENT BY APPLICANT Filing Date November 13, 2003 Doris Brugger First Name Inventor (Use several sheets if necessary) Group Art Unit 1764 Examiner Name Attorney Docket Number Sheet of 1 21487 US

NON PATENT LITERATURE DOCUMENTS

Examiner nitials' Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
-	C7	S. FOSER et al, The Pharmacacogenomics Journal, Vol. 3 pp.	
		312-319 (2003)	
	-		
•		· ·	
	1		
* *			
		·	
			ļ
	 		
			-
	+		
	1		
Examiner Signature		DATE CONSIDERED	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.

144463